Results 111 to 120 of about 35,888 (296)

Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study

Addiction Science & Clinical Practice
Background Deaths from opioid overdose have increased dramatically in the past decade. For individuals with opioid use disorder (OUD), agonist medications such as methadone and buprenorphine reduce opioid-related morbidity and mortality.
Melissa Davoust, Angela R. Bazzi, Samantha Blakemore, Juliana Blodgett, Anna Cheng, Sarah Fielman, Kara M. Magane, Jacqueline Theisen, Richard Saitz, Alicia S. Ventura, Zoe M. Weinstein   +10 more
doaj   +1 more source

Research progress on the depth of anesthesia monitoring based on the electroencephalogram

Ibrain, Volume 11, Issue 1, Page 32-43, Spring 2025.
Electroencephalogram (EEG) can noninvasive, continuous, and real‐time monitor the state of brain electrical activity, and the monitoring of EEG can reflect changes in the depth of anesthesia (DOA). The development of artificial intelligence can enable anesthesiologists to extract, analyze, and quantify DOA from complex EEG data.
Xiaolan He, Tingting Li, Xiao Wang
wiley   +1 more source

Linking people with opioid use disorder to medication treatment : a technical package of policy, programs, and practices [PDF]

Millions of Americans are living with opioid use disorder (OUD). Fortunately, medications for opioid use disorder (MOUD) approved by the Food and Drug Administration can effectively treat OUD, reduce illicit opioid use or prescription opioid misuse, and ...

core  

A mixed-method exploratory assessment of provider-based stigma of opioid use disorder (OUD) and support for medications for opioid use disorder (MOUD) in carceral settings

Harm Reduction Journal
Background In 2019, the state of Maryland passed legislation requiring local detention centers to offer medications for opioid use disorder (MOUD) to all incarcerated individuals who met criteria for opioid use disorder (OUD).
Katherine J. McLean, Nathan E. Kruis, Eric Weintraub, Heather Fitzsimons, Christopher Welsh, Natalie Spicyn, Brook Kearley, William Altekruse, Nicholas Rowland, Annabelle Belcher   +9 more
doaj   +1 more source

Comparing functionality, anxiety and depression during pregnancy and postpartum in women with hypertensive disorders: Findings from the WOICE assessment

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To describe the use of the WOICE tool for assessing non‐severe maternal morbidities among pregnant and postpartum women with hypertensive disorders. Methods Secondary analysis of a previously published cross‐sectional study performed in Brazil, with the inclusion of women with hypertensive disorders (pre‐eclampsia, chronic ...
Stephanie Pabón Lozano, José Paulo Siqueira Guida, Charles Mpoca Charles, Helen Johana Ortiz Rojas, Carolina Gómez Muñoz, Jose Guilherme Cecatti, Maria Laura Costa   +6 more
wiley   +1 more source

Int J Drug Policy [PDF]

Background:The United States overdose crisis continues unabated. Despite efforts to increase capacity for treating opioid use disorder (OUD) in the U.S., how actual treatment receipt compares to need remains unclear.

core  

Opioid Use Disorder (OUD) and Pregnancy in Utah [PDF]

, 2021
Over the past twenty years, opioid use during pregnancy has become much more common (Haight et al., 2018). Opioids may be prescribed for pain management or the treatment of an opioid use disorder (OUD).
Madden, Erin Fanning, Prevedel, Suzanne, Sulzer, Sandra H., Murza, Gabriela, Margetts, Saralyn, Hymas, Lauran, Zaman, Katie   +6 more
core   +1 more source

Induction of Medication for Opioid Use Disorder in Primary Care

The Journal of the American Board of Family Medicine
Overdoses and deaths from synthetic opioids grew sharply in the past decade. Most people with opioid use disorder (OUD) do not receive recommended evidence-based treatment: nationally, 72% to 87% of people who need OUD treatment do not receive medication for opioid use disorder (MOUD). Little is known about practice teams' experiences with home, office,
Hall, Tristen L., Fernald, Douglas H., Jiang, Vivian, Curcija, Kristen, LeMaster, Joseph W., Westfall, John M., Nease, Donald E., Zittleman, Linda   +7 more
openaire   +3 more sources

Transdiagnostic and symptom‐domain associations between mental illnesses and future self‐connectedness versus future self‐valence

JCPP Advances, EarlyView.
Abstract Background Future time perspective dimensions have been linked to various mental illnesses. Given the tendency for mental illnesses to co‐occur, it is necessary to disentangle associations between future‐oriented constructs and shared versus symptom‐domain‐specific psychopathology.
Yi Yang, Ingrid Obsuth, Jean‐Louis van Gelder, Denis Ribeaud, Manuel Eisner, Xinxin Zhu, Aja Louise Murray   +6 more
wiley   +1 more source

Nurse Practitioners and Opioid Use Disorder [PDF]

Since the 1990s, the opioid epidemic has seen increase in the number of opioid-related deaths. Currently, the only approved treatment for opioid use disorder (OUD) is Medication Assisted Treatment (MAT). The need for providers to be more comfortable with
Louisa Tali, and Juanita Takeno
core